CompletedNot Applicable

Adjuvant Ultra-Hypofractionated vs Hypofractionated Radiotherapy for Early Breast Cancer

Egypt60 participantsStarted 2023-11-27

Plain-language summary

breast-conserving surgery. One group receives ultra-hypofractionated radiotherapy (26 Gy in 5 sessions over 1 week), while the other group receives hypofractionated radiotherapy (40 Gy in 15 sessions over 3 weeks). The study aims to compare skin toxicity, cosmetic outcomes, and local cancer control between thetwo schedules . Participants are followed during and after radiotherapy for up to 24 months.

Who can participate

Age range

18 Years – 80 Years

Sex

FEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria:• Histological diagnosis of breast adenocarcinoma * Prior breast conservative surgery negative resection margins (3 mm) * Pathological stage pT1-pT2, N0-1, pT3-N0, M0 * No macroscopic evidence of distant metastases at diagnosis * Age 18-80 years * Female patients * Normal hematological and biochemical laboratory tests * Written informed consent was obtained from all patients Exclusion Criteria: • Patients underwent mastectomy. * Locally advanced disease pT4, N2,3. * Positive surgical margins * Prior thoracic radiation * Synchronous second primary tumor * Distant metastases * Pregnancy * Presence of a concomitant psychiatric disorder precluding an aware informed consent. * Age \>80 years * Low risk patient meeting all the following criteria (more than or equal 65 years, PT1, grade 1 or 2, +ER, -Her2nu, N0, M0).

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Acute Skin Toxicity (CTCAE v5.0)

Timeframe: From start of radiotherapy to 6 weeks post-treatment

Trial details

NCT IDNCT07274800

SponsorZagazig University

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2025-11-27

View on ClinicalTrials.gov More Breast Cancer trials